Non-immunogenic staphylokinase in the high-risk pulmonary embolism treatment with subdural hematoma

Non-immunogenic staphylokinase in the high-risk pulmonary embolism treatment with subdural hematoma

Aim. To evaluate the safety and efficacy of the non-immunogenic staphylokinase in a patient with a massive high-risk pulmonary embolism (PE) with subdural hematoma.Material and methods. Non-immunogenic staphylokinase (Fortelyzin®, LLC “SuperGene”, Russia) is an original thrombolytic drug with high f...

Full description

Saved in:
Bibliographic Details
Main Authors: S. L. Konstantinov, Zh. Yu. Chefranova, G. I. Stryabkova, S. A. Pribylov, I. B. Kovalenko, E. V. Gavrilyuk, S. V. Ivanov, S. S. Markin
Format: Article
Language:English
Published: Столичная издательская компания 2025-08-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
non-immunogenic staphylokinase
pulmonary embolism
hematoma
bleeding risk
thrombolytic therapy
elderly patients
safety outcomes
hemorrhagic complications
Online Access:https://www.rpcardio.online/jour/article/view/3185
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.rpcardio.online/jour/article/view/3185

Similar Items